RIGL Rigel Pharmaceuticals
- 0.955
- +0.053+5.82%
- 0.930
- -0.025-2.64%
Rigel Pharmaceuticals News
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Joseph Pantginis maintains $Rigel Pharmaceuticals(RIGL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA(olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) ...
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at...
Rigel Pharmaceuticals' Strategic Resolutions at 2024 Annual Meeting
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology...
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Rigel Pharmaceuticals (RIGL), as it has been recently upgraded to a Zacks Rank #2 (Buy).
US$5.15 - That's What Analysts Think Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Is Worth After These Results
The analysts might have been a bit too bullish on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), given that the company fell short of expectations when it released its first-quarter results last week.
Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Express News | Rigel Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Rigel Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 1263.64% HC Wainwright & Co. → $15 Reiterates Buy → Buy 03/07/2024 263.64% Citigroup $3 → $4 Ma
Earnings Call Summary | Rigel Pharmaceuticals(RIGL.US) Q1 2024 Earnings Conference
The following is a summary of the Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript:Financial Performance:Rigel reported a decrease in net product sales for TAVALISSE, with Q1 2024 s
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...
Rigel Pharmaceuticals | 10-Q: Quarterly report
Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 37.5 percent increase over losses
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, Vs. Street Est of $31.5M
04:16 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M
Express News | Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Rigel Pharmaceuticals Q1 Net Income USD -8.2 Million Vs. Ibes Estimate USD -5.36 Million
Analysis
Price Target
No Data
